amelubant

structure in first source

Also Known As:

((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)carbamic acid ethyl ester; BIIL 284; BIIL 284 BS; BIIL-284; BIIL-284 BS

Networked: 8 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Carbamates: 945
      - amelubant: 8
- Amidines: 14
  - amelubant: 8

Experts

1.	Aktürk, Firdevs-Fatma: 1 article (03/2014)
2.	Bhattacharya, S: 1 article (03/2014)
3.	Bilton, Diana: 1 article (03/2014)
4.	Born, Torsten: 1 article (03/2014)
5.	Bragonzi, Alessandra: 1 article (03/2014)
6.	Cigana, Cristina: 1 article (03/2014)
7.	Döring, G: 1 article (03/2014)
8.	Döring, Gerd: 1 article (03/2014)
9.	Elborn, J Stuart: 1 article (03/2014)
10.	Gilpin, Deirdre: 1 article (03/2014)

Related Diseases

1.	Lung Diseases (Lung Disease) 01/01/2005 - "However, a randomized, double-blind, placebo-controlled, multinational, phase II trial (Boehringer Ingelheim 543.45) was conducted to investigate the clinical efficacy of 24 weeks of treatment with amelubant in patients with CF with mild-to-moderate lung disease. " 03/01/2014 - "CF patients aged ≥6 years with mild to moderate lung disease were randomized to oral BIIL 284 BS or placebo once daily for 24 weeks. " 03/01/2014 - "A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis."
2.	Cystic Fibrosis (Mucoviscidosis) 03/01/2014 - "A clinical study to investigate the leukotriene B(4) (LTB(4))-receptor antagonist BIIL 284 in cystic fibrosis (CF) patients was prematurely terminated due to a significantly increased risk of adverse pulmonary events. " 03/01/2014 - "A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis."
3.	Infections 03/01/2014 - "While the cause of increased SAEs and exacerbations due to BIIL 284 BS is unknown, the outcome of this trial provides a cautionary tale for the administration of potent anti-inflammatory compounds to individuals with chronic infections, as the potential to significantly suppress the inflammatory response may increase the risk of infection-related adverse events."
4.	Persistent Infection 03/01/2014 - "While the cause of increased SAEs and exacerbations due to BIIL 284 BS is unknown, the outcome of this trial provides a cautionary tale for the administration of potent anti-inflammatory compounds to individuals with chronic infections, as the potential to significantly suppress the inflammatory response may increase the risk of infection-related adverse events."
5.	Rheumatoid Arthritis 05/01/2007 - "Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis." 02/01/2004 - "Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis."

Related Drugs and Biologics

1.	Leukotriene B4 Receptors (Leukotriene B4 Receptor)
2.	Leukotrienes
3.	Leukotriene B4
4.	verlukast
5.	WEB 2086 (apafant)